IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. 2004

Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Bethesda, MD 20814, USA.

IL-15 and IL-2 possess similar properties, including the ability to induce T cell proliferation. However, whereas IL-2 can promote apoptosis and limit CD8(+) memory T cell survival and proliferation, IL-15 helps maintain a memory CD8(+) T cell population and can inhibit apoptosis. We sought to determine whether IL-15 could enhance the in vivo function of tumor/self-reactive CD8(+) T cells by using a T cell receptor transgenic mouse (pmel-1) whose CD8(+) T cells recognize an epitope derived from the self/melanoma antigen gp100. By removing endogenous IL-15 by using tumor-bearing IL-15 knockout hosts or supplementing IL-15 by means of exogenous administration, as a component of culture media or as a transgene expressed by adoptively transferred T cells, we demonstrate that IL-15 can improve the in vivo antitumor activity of adoptively transferred CD8(+) T cells. These results provide several avenues for improving adoptive immunotherapy of cancer in patients.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008562 Membrane Glycoproteins Glycoproteins found on the membrane or surface of cells. Cell Surface Glycoproteins,Surface Glycoproteins,Cell Surface Glycoprotein,Membrane Glycoprotein,Surface Glycoprotein,Glycoprotein, Cell Surface,Glycoprotein, Membrane,Glycoprotein, Surface,Glycoproteins, Cell Surface,Glycoproteins, Membrane,Glycoproteins, Surface,Surface Glycoprotein, Cell,Surface Glycoproteins, Cell
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females

Related Publications

Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
January 2016, Oncoimmunology,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
September 2023, Nature cancer,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
September 2010, Journal of leukocyte biology,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
February 2003, Blood,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
January 2017, Molecular therapy : the journal of the American Society of Gene Therapy,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
February 2008, Journal of immunology (Baltimore, Md. : 1950),
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
January 2023, Frontiers in immunology,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
January 2022, Frontiers in immunology,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
January 2005, Cytotherapy,
Christopher A Klebanoff, and Steven E Finkelstein, and Deborah R Surman, and Michael K Lichtman, and Luca Gattinoni, and Marc R Theoret, and Navrose Grewal, and Paul J Spiess, and Paul A Antony, and Douglas C Palmer, and Yutaka Tagaya, and Steven A Rosenberg, and Thomas A Waldmann, and Nicholas P Restifo
August 2010, Journal of molecular cell biology,
Copied contents to your clipboard!